TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20577750
Drug: Vaginal suppositories
Normalized name: Miconazole Nitrate Vaginal Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppositories containing genistein (97 μg daily for 15 days/month for 3 months)
Study: 20577750
Drug: Vaginal suppositories
Normalized name: Miconazole Nitrate Vaginal Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppositories containing hyaluronic acid (5 mg daily for 15 days/month for 3 months)
Study: 19344224
Drug: Intravenous EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous EPO (30,000 U) every 48 hours for a total of 90,000 U
Study: 16765169
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg orally 1 hour before UDS
Study: 16281654
Drug: alendronate/calcium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: alendronate/calcium (10 mg/600 mg day)
Study: 8109217
Drug: Ethanol ingestion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol ingestion (serum ethanol concentration of 0.98 +/- 0.22 g/l)
Study: 3311904
Drug: Single 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 g dose tetracycline
Study: 3311904
Drug: Single 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2 g dose tetracycline
Study: 3311904
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose tetracycline (500 mg every six hours, four times)
Study: 26732944
Drug: CINV control
Normalized name: Cinvanti
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CINV control (total control: no vomiting, no nausea, and no rescue medication)
Study: 24622816
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) performed three times daily for 5 days at a dosage of 1.4 J/cm(2)
Study: 22297422
Drug: Brucella abortus
Normalized name: BRUCELLA ABORTUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brucella abortus strain RB51 vaccine (recommended vaccine dose twice 4 weeks apart)
Study: 22297422
Drug: Brucella abortus
Normalized name: BRUCELLA ABORTUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brucella abortus strain RB51 vaccine (recommended vaccine dose twice 18 weeks apart)
Study: 17451339
Drug: Retroperitoneoscopic nephrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retroperitoneoscopic nephrectomy (RN) for giant hydronephrosis (GH); mean operating time 126 minutes (range 65-240 minutes), estimated blood loss 101 mL (range 5-450 mL), mean length of hospital stay 2.9 days (range 1.5-6 days).
Study: 17451339
Drug: Retroperitoneoscopic nephrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retroperitoneoscopic nephrectomy (RN) for small nonfunctioning kidneys (SNFK); mean operating time 116 minutes (range 55-270 minutes), estimated blood loss 46 mL (range 5-400 mL), mean length of stay 2.8 days (range 1-5 days).
Study: 15694571
Drug: Appropriate care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate care with hylan G-F 20 (AC+H)
Study: 15694571
Drug: Appropriate care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate care without hylan G-F 20 (AC)
Study: 779465
Drug: Live, oral,
Normalized name: Adenovirus Vaccine, Live, Oral, Type 4
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, oral, streptomycin-dependent Shigella sonnei vaccine
Study: 22950667
Drug: Iota-carrageenan nasal
Normalized name: iota-Carrageenan
DrugBank: iota-Carrageenan (DB15304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iota-carrageenan nasal spray (0.12%)
Study: 17414581
Drug: Nifedipine microgranules
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine microgranules (NMG) 30 mg/day
Study: 17414581
Drug: Nifedipine osmotic
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine osmotic pump (NOP) 30 mg/day
Study: 15992694
Drug: Postoperative regional
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative regional chemotherapy with fluorouracil followed by systemic chemotherapy with fluorouracil and folinic acid (n=368) or with fluorouracil and levamisole (n=380).
Study: 15992694
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy alone (379 with fluorouracil and folinic acid, and 374 with fluorouracil and levamisole).
Study: 15992694
Drug: Regional chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional chemotherapy (intraperitoneal or intraportally).
Study: 15992694
Drug: Non-regional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-regional treatment (systemic chemotherapy alone).
Study: 15992694
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including both regional and systemic chemotherapy).
Study: 10472217
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin and gentamicin-vancomycin antibiotic prophylaxis (Group D)
Study: 10472217
Drug: Cefamandole and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole and high-dose aprotinin (Group B)
Study: 1833901
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg captopril (C)
Study: 1833901
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg captopril (C)
Study: 1833901
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg enoximone (E)
Study: 1833901
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg enoximone (E)
Study: 6315025
Drug: suloctidil 200
Normalized name: suloctidil
DrugBank: Suloctidil (DB13340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: suloctidil 200 mg three times per day
Study: 30137262
Drug: Video-Guided Acupuncture
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-Guided Acupuncture Imagery Treatment (VGAIT)
Study: 29845877
Drug: AIHA patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIHA patients with partial or no response to therapy (CD8+CD57+ cells frequency)
Study: 27310905
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive treatment (systolic BP < 120 mmHg)
Study: 27310905
Drug: Less intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intensive treatment (systolic BP < 140 mmHg)
Study: 24632748
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with oseltamivir and azithromycin (AZM)
Study: 12519138
Drug: i.v. buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. buprenorphine 2.5 micro g.kg‐1 (group B)
Study: 12519138
Drug: caudal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: caudal buprenorphine 2.5 micro g.kg‐1 (group C)
Study: 10354967
Drug: IL-10 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 with prednisone (15 mg p.o.)
Study: 30694918
Drug: TX-001HR (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-001HR (oral estradiol and progesterone capsules) 1 mg/100 mg
Study: 30694918
Drug: TX-001HR (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-001HR (oral estradiol and progesterone capsules) 0.5 mg/100 mg
Study: 30694918
Drug: TX-001HR (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-001HR (oral estradiol and progesterone capsules) 1 mg/100 mg (phase 1 study)
Study: 30694918
Drug: TX-001HR (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-001HR (oral estradiol and progesterone capsules) 0.5 mg/100 mg (phase 1 study)
Study: 30694918
Drug: TX-001HR (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-001HR (oral estradiol and progesterone capsules) 1 mg/100 mg and 0.5 mg/100 mg
Study: 30694918
Drug: TX-001HR (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-001HR (oral estradiol and progesterone capsules)
Study: 28485429
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg PI2
Study: 28485429
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg PI2
Study: 25559067
Drug: Lunchtime walks
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lunchtime walks (three weekly 30-min group-led walks for 10 weeks)
Study: 25559067
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (control period)
Study: 19825330
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (LC) 2,250 to 3,000 mg/day
Study: 19825330
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride (SH) 4,800 to 6,400 mg/day
Study: 8422223
Drug: Alprazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (mean dose, 5.2 mg, n = 27)
Study: 8422223
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride (mean dose, 175 mg, n = 11)
Study: 8422223
Drug: Placebo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mean dose, 8.0 pills, n = 10)
Study: 8422223
Drug: Alprazolam (follow-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (follow-up mean daily dose, 6.1 mg vs 1.6 mg, n = 14)
Study: 8422223
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (8-month completers and study dropouts)
Study: 31183389
Drug: 48 mg
Normalized name: betaine 648 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 mg sucralose dissolved in 60 mL water
Study: 31183389
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL water as placebo
Study: 26583672
Drug: Octreotide acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide acetate (100 μg) subcutaneously
Study: 26583672
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline, 1 mL)
Study: 21639607
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment alliance scores
Study: 19324125
Drug: Intermittent bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bupivacaine administration (30 mL every 6 hours)
Study: 19324125
Drug: Continuous bupivacaine
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bupivacaine infusion (5 mL/h)
Study: 19324125
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no local anesthetic infusion)
Study: 12634667
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg three times daily
Study: 3020832
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam administration (10 mg)
Study: 16707411
Drug: Novel matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel matrix transdermal formulation of fentanyl (50 mug/h)
Study: 16707411
Drug: Conventional reservoir
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional reservoir formulation of fentanyl
Study: 14504680
Drug: Hydrocortisone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (20 mg, administered twice daily for 7 days)
Study: 11826514
Drug: Brief intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief intervention to help formulate questions about drug therapy
Study: 8277179
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg orally twice a day)
Study: 4274488
Drug: Lumbar rotational
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumbar rotational manipulation followed by four daily detuned short-wave diathermy sessions (15 minutes each)
Study: 4274488
Drug: Detuned short-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detuned short-wave diathermy only (five 15-minute daily sessions)
Study: 25589719
Drug: Nutraceutical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical formulation (NF; folate, alpha‐tocopherol, B12, S‐adenosyl methionine, N‐acetyl cysteine, acetyl‐L‐carnitine)
Study: 20948588
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with monomeric allergoid (three different shortened up-dosing schedules)
Study: 20948588
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sublingual immunotherapy, only rescue medications)
Study: 18371477
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/d for 1 year after a 300 mg loading dose before PCI
Study: 18371477
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/d for 28 days and placebo for the remainder of a year after a placebo loading dose at the time of PCI
Study: 8941027
Drug: Thioridazine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine 1.0 mg
Study: 1327980
Drug: Propranolol (non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (non-selective beta adrenergic antagonist)
Study: 1327980
Drug: Atenolol (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (selective beta-1 antagonist)
Study: 1327980
Drug: Isoprenaline (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (beta adrenoreceptor agonist)
Study: 3894481
Drug: Albuterol/theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol/theophylline
Study: 31342499
Drug: Health promotion
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health promotion education group activities (90 minutes, twice a week for 8 sessions)
Study: 31342499
Drug: Routine dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine dialysis treatment and nursing care
Study: 23730808
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training + Testosterone (50-100 mg/d)
Study: 23730808
Drug: Testosterone only
Normalized name: Testosterone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone only (50-100 mg/d)
Study: 16029381
Drug: Epinephrine at
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine at 2 mcg/min
Study: 16029381
Drug: Norepinephrine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine at 2 mcg/min
Study: 12874742
Drug: Oral kilocalorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral kilocalorie and protein supplementation for 3 months (treatment group)
Study: 12874742
Drug: Oral kilocalorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral kilocalorie and protein supplementation (treatment group)
Study: 2146231
Drug: Trospectomycin 250
Normalized name: TROSPECTOMYCIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospectomycin 250 mg
Study: 2146231
Drug: Trospectomycin 500
Normalized name: TROSPECTOMYCIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospectomycin 500 mg
Study: 2146231
Drug: Trospectomycin 750
Normalized name: TROSPECTOMYCIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospectomycin 750 mg
Study: 31931884
Drug: LINC‐II intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: LINC‐II intervention (strengths‐based HIV case management, rapid ART initiation, pharmacotherapy for opioid use disorder)
Study: 9110007
Drug: IV ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketorolac (1 mg/kg)
Study: 3543161
Drug: Acedapsone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acedapsone (3 injections at 10 weeks interval)
Study: 3543161
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 injections at 10 weeks interval)
Study: 29362929
Drug: Multimodal ADHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal ADHD treatment (group psychotherapy plus methylphenidate)
Study: 25523036
Drug: ORAL IMPACT®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORAL IMPACT® (preoperative oral immunonutrition)
Study: 25523036
Drug: IMPACT CONTROL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPACT CONTROL® (isocaloric isonitrogenous supplement)
Study: 21880080
Drug: Lactulose (L)
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose (L)
Study: 18296130
Drug: Intravenous prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prednisolone, 40-60 mg/day for 5-10 days (n = 35)
Study: 16158009
Drug: DemTect cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: DemTect cutoff score of ≤13 points for AD-typical patterns of cerebral glucose metabolism
Study: 11843742
Drug: Intranasal PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal PCA diamorphine (1.0 mg bolus, 3 min lockout)
Study: 11843742
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA diamorphine (0.5 mg bolus, 3 min lockout)
Study: 29667211
Drug: Celecoxib 100-200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100-200 mg b.d.
Study: 29667211
Drug: Ibuprofen 600-800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600-800 mg t.d.s.
Study: 29667211
Drug: Naproxen 375-500
Normalized name: naproxen 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 375-500 mg b.d.
Study: 20716305
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg per week of oral naltrexone plus standard psychosocial treatment as usual (n = 56)
Study: 20716305
Drug: Standard psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psychosocial treatment as usual (TAU) without naltrexone (n = 55)
Study: 12021498
Drug: Heptavalent pneumococcal
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent pneumococcal CRM 197 conjugate vaccine
Study: 9042984
Drug: Alginate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate (2 x 250 mg chewable tablets)
Study: 7836717
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (four doses)
Study: 29550020
Drug: Topical dipyrone
Normalized name: dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dipyrone gel
Study: 23656980
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin glargine
Study: 20158586
Drug: sulfasalazine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfasalazine (maximum 2.5 g/day)
Study: 17012867
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever 17D vaccine
Study: 11783327
Drug: HANS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HANS plus small dose of buprenorphine (BPN)
Study: 9595795
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration by nasal cannula during the first or second postoperative night
Study: 9595795
Drug: No oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oxygen therapy (control group)
Study: 8357297
Drug: Alprazolam (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (titrated upward to reach 6.0 mg/d)
Study: 2877953
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg per day dihydroergotamine
Study: 31410765
Drug: Lozenges containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenges containing Lactobacillus reuteri taken twice daily for 90 days
Study: 21451152
Drug: EZG(RTG) 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZG(RTG) 1,200 mg/day
Study: 15301297
Drug: Oral food
Normalized name: Nutritional Supplement Oral Food, Solid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral food challenges (cow milk, hen egg, wheat)
Study: 8996417
Drug: USA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: USA treatment
Study: 8996417
Drug: Other countries
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other countries treatment
Study: 8491245
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg (Group 1, n = 6)
Study: 8491245
Drug: Doxazosin 2
Normalized name: doxazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 2 mg (Group 2, n = 6)
Study: 8491245
Drug: Doxazosin 2
Normalized name: doxazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 2 mg (Group 2) with addition of Nifedipine
Study: 8491245
Drug: Doxazosin 2
Normalized name: doxazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 2 mg (Group 2)
Study: 26755229
Drug: Colloid preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid preload with 0.5 L of 6% w/v hydroxyethyl starch solution
Study: 26755229
Drug: Prophylactic IV
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic IV infusion of 15 mg ephedrine
Study: 16641468
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (Boost Plus)
Study: 10026369
Drug: Continuous 6-ppm
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 6-ppm dose of inhaled nitric oxide (iNO)
Study: 10026369
Drug: Either treatment
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either treatment